Trial Profile
Efficacy and safety of meningococcal vaccine group B OMV developed for New Zealand epidemic strain in infants.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Feb 2015
Price :
$35
*
At a glance
- Drugs Meningococcal vaccine group B OMV Novartis (Primary) ; Meningococcal vaccine group C conjugate
- Indications Meningococcal infections
- Focus Pharmacodynamics
- 05 Nov 2010 New trial record.